Deferasorox (deferasirox) NDC 72205-176

NDC codes

FDA NDC Directory

Product NDC (as listed)72205-176Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72205-0176Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72205-176-30	72205017630	30 PACKET in 1 CARTON (72205-176-30) / 1 GRANULE in 1 PACKET (72205-176-61)Marketed from May 21, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Deferasorox
Generic name (nonproprietary): deferasirox
Active ingredients: Deferasirox — 90 mg/1
Dosage form: Granule
Route: Oral
Labeler: Novadoz Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214650
Marketing start: May 21, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 1A2 Inhibitors (Mechanism)Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Iron Chelating Activity (Mechanism)
Identifiers: Product ID 72205-176_b2ff1a76-b564-4235-8275-89005d9c4a24SPL ID b2ff1a76-b564-4235-8275-89005d9c4a24SPL set ID 1122f1c0-c160-49db-a31b-90d7521370f5RxCUI 1923822, 1923826, 1923828UNII V8G4MOF2V9UPC 0372205076617, 0372205176614, 0372205075610
Pharmacologic class: Iron Chelator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472205017630 followed by a unit qualifier and the quantity

Package 72205-0176-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 20, 2022. This label includes a boxed warning.

Indications (excerpt from the label)

Deferasirox oral granules are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox oral granules are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of deferasirox oral granules when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Ove…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214650

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214650
Product	Strength	Form · route	Labeler	Product NDC
Deferasoroxdeferasirox	Deferasirox 180 mg/1	GranuleOral	Novadoz Pharmaceuticals LLC	72205-075
Deferasoroxdeferasirox	Deferasirox 360 mg/1	GranuleOral	Novadoz Pharmaceuticals LLC	72205-076